Assessment of cytokines in human islets from patients with diabetes
Assessment of cytokines in human islets from patients with diabetes
批准号:
8501368
负责人:
Matthias G. Von Herrath
金额:
$42.31万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-09-20 至 2017-06-30
关键词:
AffectAnimal ModelAntibodiesAntigensAtlasesAutoimmune DiseasesBeta CellBiologicalBiological PreservationBiopsyCellsCollaborationsCombined Modality TherapyComplementComplementary DNACrohn&aposs diseaseDataDendritic CellsDetectionDiabetes MellitusDiseaseDissectionEnvironmentEpitopesEventExtravasationFloridaFormalinFreezingFutureGenerationsGenesHumanImmuneImmune ToleranceImmunizationImmunohistochemistryIn SituIn Situ HybridizationInflammatoryInsulin-Dependent Diabetes MellitusInterventionIslet CellIslets of LangerhansJointsLabelLasersLearningLesionLeukocytesLinkMediatingMessenger RNAMicrodissectionModelingNatural Killer CellsNon-Insulin-Dependent Diabetes MellitusNucleic Acid ProbesOrganOrgan DonorOutcomePancreasParaffin EmbeddingPathogenesisPatientsPatternPharmaceutical PreparationsPreparationProceduresProteinsPsoriasisRNARegimenRegulatory T-LymphocyteResearchRheumatoid ArthritisSamplingSignal TransductionSiteStagingStaining methodStainsSynovial CellT-LymphocyteTNF geneTechniquesTestingTherapeuticTimeTissue SampleTissuesUncertaintyUniversitiesbasecell typechemokinecytokinedesignexperiencehuman tissueinhibitor/antagonistinsightisletmacrophagenon-diabeticpublic health relevancerepositoryrestorationtherapeutic targettherapy developmenttooltype I and type II diabetes
中文摘要
描述(由申请人提供):免疫介导疾病治疗的合理开发最佳基于对发病机制的详细理解,特别是受影响器官或组织中的免疫事件。在1型(以及2型)糖尿病中,这迄今为止受到患者胰腺的可获得性和可用性的阻碍。然而,最近建立的胰腺器官捐献者库(“nPOD”)彻底改变了这种情况,并为加深我们对人类状况的了解提供了一个至关重要的机会-这不仅将缩小差距,而且将(并且已经)改变范式,使我们能够以更有针对性的方式设计基于免疫的干预措施。因此,在这里,我们希望评估哪些细胞因子在1型和2型糖尿病患者的人类胰腺中表达。我们将使用一系列的策略来确定可靠的结果,包括直接原位免疫组织学,原位杂交,定量PCR以及激光显微切割。这些研究应该确定在人类1型和2型糖尿病发病过程中表达的主要细胞因子,表达它们的细胞以及它们的表达是否是组成性的或与疾病的某个阶段相关,或者更可能是局部胰岛破坏的阶段。直接鉴定关键免疫病理学因子作为受影响器官中的未来治疗靶标的策略已有先例,因为这是类风湿性关节炎的情况,其中TNF阻断剂是基于Marc Feldman对类风湿性关节炎中受影响关节的滑膜细胞中TNF水平升高的初步观察而开发的。从翻译的角度来看,我们设想细胞因子阻断可以整合在联合治疗中,旨在长期诱导耐受性,理想地补充诱导调节性T细胞的免疫方案。
英文摘要
DESCRIPTION (provided by applicant): Rational development of treatments for immune mediated diseases is optimally based on detailed understanding of the pathogenesis, especially immunological events in affected organs or tissues. In type 1 (as well as type 2) diabetes, this has been hampered so far by access to and availability of pancreata from patients. However, the recently established repository of pancreatic organ donors ('nPOD') has drastically changed this situation and offers a crucial opportunity to deepen our insight into the human condition - this will not only close gaps, but will (and already has) shift paradigms and enable us to design immune-based interventions in a more targeted fashion. Therefore here, we wish to assess, which cytokines are expressed in human pancreata of patients with type 1 and type 2 diabetes. We will use a combination of strategies to ascertain reliable results including direct in situ immunohistology, in situ hybridization, quantitative PCR as well as laser microdissection. These studies should identify the major cytokines expressed during pathogenesis of human type 1 and type 2 diabetes, the cells which express them and whether their expression is constitutive or linked to a certain stage of the disease or, more likely, stage of local islet destruction. The strategy of directly identifying pivotal immunopathological factors as future therapeutic targets i the affected organ has precedent, as this has been the case for rheumatoid arthritis, where TNF blockers were developed based on Marc Feldman's initial observation of heightened TNF levels in synovial cells from affected joints in rheumatoid arthritis. From a translational angle, we envision that cytokine blockade could be integrated in a combination therapy aimed at long term tolerance induction, ideally complementing immunization regimens that induce regulatory T cells.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Treg stability in viral infection and autoimmunity
-
批准号:8495227
-
项目类别:
-
资助金额:$43.73万
-
财政年份:2013
-
负责人:Matthias G. Von Herrath
-
依托单位:
Treg stability in viral infection and autoimmunity
-
批准号:8377922
-
项目类别:
-
资助金额:$46.53万
-
财政年份:2012
-
负责人:Matthias G. Von Herrath
-
依托单位:
Specificity of CD8 cells in islets from type 1 diabetes patients
-
批准号:8655830
-
项目类别:
-
资助金额:$40.14万
-
财政年份:2011
-
负责人:Matthias G. Von Herrath
-
依托单位:
Specificity of CD8 cells in islets from type 1 diabetes patients
-
批准号:8261913
-
项目类别:
-
资助金额:$40.14万
-
财政年份:2011
-
负责人:Matthias G. Von Herrath
-
依托单位:
Specificity of CD8 cells in islets from type 1 diabetes patients
-
批准号:8195256
-
项目类别:
-
资助金额:$40.14万
-
财政年份:2011
-
负责人:Matthias G. Von Herrath
-
依托单位:
Specificity, Phenotype and Function of Pancreatic CD8 T Cells in Human Type 1 Diabetes
-
批准号:9238399
-
项目类别:
-
资助金额:$45.0万
-
财政年份:2011
-
负责人:Matthias G. Von Herrath
-
依托单位:
Specificity of CD8 cells in islets from type 1 diabetes patients
-
批准号:8451478
-
项目类别:
-
资助金额:$37.73万
-
财政年份:2011
-
负责人:Matthias G. Von Herrath
-
依托单位:
Specificity of CD8 cells in islets from type 1 diabetes patients
-
批准号:8828063
-
项目类别:
-
资助金额:$40.14万
-
财政年份:2011
-
负责人:Matthias G. Von Herrath
-
依托单位:
Specificity, Phenotype and Function of Pancreatic CD8 T Cells in Human Type 1 Diabetes
-
批准号:10061526
-
项目类别:
-
资助金额:$45.0万
-
财政年份:2011
-
负责人:Matthias G. Von Herrath
-
依托单位:
Treg stability in viral infection and autoimmunity
-
批准号:8006796
-
项目类别:
-
资助金额:$41.15万
-
财政年份:2010
-
负责人:Matthias G. Von Herrath
-
依托单位:
How IL-10R blockade can resolve persistent viral infections
-
批准号:7919813
-
项目类别:
-
资助金额:$20.7万
-
财政年份:2009
-
负责人:Matthias G. Von Herrath
-
依托单位:
Viruses and Autoimmunity POI
-
批准号:7923514
-
项目类别:
-
资助金额:$45.7万
-
财政年份:2009
-
负责人:Matthias G. Von Herrath
-
依托单位:
How IL-10R blockade can resolve persistent viral infections
-
批准号:7667337
-
项目类别:
-
资助金额:$41.72万
-
财政年份:2007
-
负责人:Matthias G. Von Herrath
-
依托单位:
How IL-10R blockade can resolve persistent viral infections
-
批准号:7487519
-
项目类别:
-
资助金额:$41.72万
-
财政年份:2007
-
负责人:Matthias G. Von Herrath
-
依托单位:
How IL-10R blockade can resolve persistent viral infections
-
批准号:7313053
-
项目类别:
-
资助金额:$42.53万
-
财政年份:2007
-
负责人:Matthias G. Von Herrath
-
依托单位:
How IL-10R blockade can resolve persistent viral infections
-
批准号:7914240
-
项目类别:
-
资助金额:$41.3万
-
财政年份:2007
-
负责人:Matthias G. Von Herrath
-
依托单位:
Achieving Therapeutic Antigent-Specific Tolerance in Type 1 Diabetes
-
批准号:7469963
-
项目类别:
-
资助金额:$43.11万
-
财政年份:2006
-
负责人:Matthias G. Von Herrath
-
依托单位:
Achieving Therapeutic Antigent-Specific Tolerance in Type 1 Diabetes
-
批准号:7289765
-
项目类别:
-
资助金额:$42.71万
-
财政年份:2006
-
负责人:Matthias G. Von Herrath
-
依托单位:
Assessment of cytokines in human islets from patients with diabetes
-
批准号:8373378
-
项目类别:
-
资助金额:$44.77万
-
财政年份:2006
-
负责人:Matthias G. Von Herrath
-
依托单位:
Achieving Therapeutic Antigent-Specific Tolerance in Type 1 Diabetes
-
批准号:7248524
-
项目类别:
-
资助金额:$42.71万
-
财政年份:2006
-
负责人:Matthias G. Von Herrath
-
依托单位:
海外基金